Omnicell Inc. (OMCL) Trading Down 2.5%
Omnicell Inc. (NASDAQ:OMCL) shares were down 2.5% during trading on Thursday . The company traded as low as $35.34 and last traded at $35.42, with a volume of 79,447 shares traded. The stock had previously closed at $36.32.
A number of research analysts recently commented on OMCL shares. FBR & Co upped their price objective on Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, July 7th. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Omnicell currently has an average rating of “Buy” and a consensus target price of $37.25.
The stock has a 50-day moving average price of $34.46 and a 200 day moving average price of $30.07. The firm has a market capitalization of $1.27 billion and a P/E ratio of 53.19.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, April 28th. The company reported $0.35 EPS for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.09. The firm earned $171 million during the quarter, compared to the consensus estimate of $167.18 million. During the same quarter in the prior year, the business posted $0.29 EPS. Omnicell’s revenue was up 47.1% compared to the same quarter last year. Equities research analysts expect that Omnicell Inc. will post $1.56 earnings per share for the current fiscal year.
In other Omnicell news, VP Jorge R. Taborga sold 1,933 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $30.73, for a total value of $59,401.09. Following the completion of the sale, the vice president now owns 52,667 shares in the company, valued at approximately $1,618,456.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robin Gene Seim sold 5,302 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $34.75, for a total value of $184,244.50. Following the completion of the sale, the executive vice president now owns 55,420 shares of the company’s stock, valued at approximately $1,925,845. The disclosure for this sale can be found here.
Several hedge funds have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System increased its stake in shares of Omnicell by 10.4% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 42,213 shares of the company’s stock worth $1,312,000 after buying an additional 3,982 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Omnicell by 1.4% in the fourth quarter. Rhumbline Advisers now owns 45,301 shares of the company’s stock worth $1,408,000 after buying an additional 620 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Omnicell by 10.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 93,675 shares of the company’s stock worth $2,910,000 after buying an additional 9,066 shares in the last quarter. Comerica Bank increased its stake in shares of Omnicell by 8.9% in the fourth quarter. Comerica Bank now owns 68,602 shares of the company’s stock worth $1,885,000 after buying an additional 5,629 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in shares of Omnicell by 32.0% in the fourth quarter. Mutual of America Capital Management LLC now owns 152,422 shares of the company’s stock worth $4,737,000 after buying an additional 36,911 shares in the last quarter.
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.